Anti-cancer protein transduction strategies: Reconstitution of p27 tumor suppressor function

Journal of Controlled Release

Volumn 91, Issue 1-2, 2003, Pages 45-51

  Snyder, Eric L ^a   Meade, Bryan R ^a   Dowdy, Steven F ^a  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

p27; Protein transduction; TAT PTD; Tumor suppressor proteins

Indexed keywords

CELLS; GENES; TUMORS;

ANTI-CANCER PROTEINS;

PROTEINS;

HYBRID PROTEIN; PROTEIN P27; TRANSACTIVATOR PROTEIN; BETA GALACTOSIDASE; CDKN1B PROTEIN, MOUSE; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN; VIRUS FUSION PROTEIN;

ADENOCARCINOMA; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CELL SPECIFICITY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; TUMOR CELL DESTRUCTION; TUMOR SUPPRESSOR GENE; ANIMAL; ARTICLE; BIOSYNTHESIS; CELL CULTURE; CELL CYCLE; CHEMISTRY; DRUG EFFECT; GENETIC TRANSDUCTION; GENETICS; METABOLISM; NUDE MOUSE; REGULATOR GENE; REPORTER GENE; SYNTHESIS;

ADENOCARCINOMA; ANIMALS; BETA-GALACTOSIDASE; CELL CYCLE; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; GENES, REPORTER; GENES, TAT; MICE; MICE, NUDE; NEOPLASM PROTEINS; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS; VIRAL FUSION PROTEINS;

EID: 0141955919     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(03)00212-8     Document Type: Conference Paper

References (25)

1. Scheld W.M. Drug delivery to the central nervous system: general principles and relevance to therapy for infections of the central nervous system. Rev. Infect. Dis. Suppl. 7:1989;1669-1681.
2. Egleton R.D., Davis T.P. Bioavailability and transport of peptides and peptide drugs into the brain. Peptides. 18:(9):1997;1431-1439.
3. van de Waterbeemd H., Camenisch G., Folkers G., Chretien J.R., Raevsky O.A. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J. Drug Target. 6:(2):1998;151-165.
4. Cirielli C., Inyaku K., Capogrossi M.C., Yuan X., Williams J.A. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of experimental intracranial human malignant glioma. J. Neurooncol. 43:(2):1999;99-108.
5. Fueyo J., Gomez-Manzano C., Yung W.K., Kyritsis A.P. Targeting in gene therapy for gliomas. Arch. Neurol. 56:(4):1999;445-448.
6. Lang F.F., Yung W.K., Sawaya R., Tofilon P.J. Adenovirus-mediated p53 gene therapy for human gliomas. Neurosurgery. 45:(5):1999;1093-1104.
7. Li D.M., Sun H. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc. Natl. Acad. Sci. USA. 95:(26):1998;15406-15411.
8. Furnari F.B., Huang H.-J.S., Cavanee W.K. The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 arrest in glioma cells. Cancer Res. 58:1998;5002-5008.
9. Stambolic V., Suzuki A., de la Pompa J.L., Brothers G.M., Mirtsos C., Sasaki T., Ruland J., Penninger J.M., Siderovski J., Mak T.W. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 95:1998;29-39.
10. Simon M., Koster G., Menon A.G., Schramm J. Functional evidence for a role of combined CDKN2A (p16-p14(ARF))/CDKN2B (p15) gene inactivation in malignant gliomas. Acta Neuropathol. 98:(5):1999;444-452.
11. Arap W., Nishikawa R., Furnari F., Cavanee W., Huang H. Replacement of p16/CDKN2 gene suppresses human glioma cell growth. Cancer Res. 55:1995;1351-1354.
12. Harada H., Nakagawa K., Iwata S., Saito M., Kumon Y., Sakaki S., Sato K., Hamada K. Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas. Cancer Res. 59:(15):1999;3783-3789.
13. Green M., Loewenstein P.M. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell. 55:(6):1988;1179-1188.
14. Frankel A.D., Pabo C.O. Cellular uptake of the tat protein from human immunodeficiency virus. Cell. 55:(6):1988;1189-1193.
15. Fawell S., Seery J., Daikh Y., Moore C., Chen L.L., Pepinsky B., Barsoum J. Tat-mediated delivery of heterologous proteins into cells. Proc. Natl. Acad. Sci. USA. 91:(2):1994;664-668.
16. Kip1 mediates cell migration. Nat. Med. 4:1998;1449-1452.
17. Snyder E.L., Dowdy S.F. Protein transduction domains: potential to deliver large DNA molecules into cells. Curr. Opin. Mol. Ther. 3:2001;147-152.
18. Wadia J.S., Dowdy S.F. Protein transduction technology. Curr. Opin. Biotechnol. 13:2002;52-56.
19. Schwarze S., Ho A., Vocero-Akbani A., Dowdy S.F. In vivo protein transduction: delivery of biologically active protein into the mouse. Science. 285:1999;1569-1572.
20. Becker-Hapak M., McAllister S., Dowdy S.F. TAT-mediated protein transduction into mammalian cells. Methods Enzymol. 24:2001;247-256.
21. Sherr C.J., Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13:(12):1999;1501-1512.
22. kip1 mediates cell motility independent of cell cycle arrest. Mol. Cell. Biol. 23:2003;216-228.
23. Nagy J.A., Masse E.M., Herzberg K.T., Meyers M.S., Yeo K.-T., Yeo T.-K., Sioussat T.M., Dvorak H.F. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res. 55:1995;360-368.
24. Parsons S.L., Watson S.A., Steele R.J.C. Malignant ascites. Br. J. Surgery. 83:1996;6-14.
25. Ho A., Dowdy S.F. Regulation of G1 cell cycle progression by oncogenes and tumor suppressors. Curr. Opin. Genet. Dev. 12:2002;47-52.